Scientists Grew a Tiny Brain That Fires Like a 40-Day-Old Fetus
In recent years, organoids—self-assembling cells developed from stem cells—have provided scientists ways to investigate diseases and disorders in the lab without the need for animal models or donated human organs.
Scientists from Johns Hopkins University have created what they call the 'next generation of brain organoids' which connect different regions of the brain into one whole-brain organoid.
Scientists hope to use this breakthrough to increase the speed and efficiency of drug trials for nueropsychiatric disorders.
Over the years, scientists have gotten increasingly more proficient at creating in vitro organoids—self-assembling, 3D cultures derived from stem cells that mimic certain organs of the brain—in an attempt to better understand these organs and the diseases and disorders that impact them. In 2022, scientists created DishBrain, an assembly of 800,000 neurons that was capable of playing the video game Pong (three years later, the company Cortical Labs released the CL-1, a computer than runs on human brain cells). Some scientists even think these organoids could display some level of consciousness.
Now, scientists at Johns Hopkins University (JHU) have developed what they describe as the 'next generation of brain organoids.' Instead of mimicking one region of the brain, the research team instead developed a 'whole brain' organoid with various regions acting in concert with one another. The researchers call this breakthrough a 'multi-region brain organoid,' or MRBO, and detail how they constructed this new kind of organoid in a study published in the journal Advanced Science.'We need to study models with human cells if you want to understand neurodevelopmental disorders or neuropsychiatric disorders, but I can't ask a person to let me take a peek at their brain just to study autism,' Annie Kathuria, senior author of the study from JHU, said in a press statement. "Whole-brain organoids let us watch disorders develop in real time, see if treatments work, and even tailor therapies to individual patients.'
To create this new kind of mini-brain, Kathuria and her team first grew neural cells for differing regions of the brain, along with rudimentary blood vessels (grown in separate petri dishes). Then, the scientists combined those different parts with a sticky protein that acted as a kind of 'biological superglue,' according to the press statement. This protein-based scaffolding allowed tissues to form connections and (eventually) electrical networks.
The resulting MRBO is far removed from a fully-formed human brain, containing only 6 to 7 million neurons instead of the tens of billions found in a typical human brain. The scientists estimate that their MRBO closely mimics the brain formation of a 40-day-old fetus, and in a fascinating twist, the researchers also saw the early formation of the blood-brain barrier—a gatekeeping layer of cells that controls what microbes and nutrients can access the brain—within the MRBO.
'This is the new generation of brain organoids, which is a great improvement to the modeling of brain development and the pathophysiology of the fetal brain,' the authors write. 'With three main regions of the brain and the endothelial system, the MRBOs allow the analysis of highly complex human brain function over time.'
The creation of MRBOs isn't to design some sort of next-gen neuromorphic computer, but to improve the success rate of drug trials. Because scientists often rely on animal models for testing drugs during Phase 1 trials, results don't always translate perfectly to humans. Having a reliable platform that more closely mimics the human brain in miniature will hopefully make drug development faster and more efficient.
'Diseases such as schizophrenia, autism, and Alzheimer's affect the whole brain, not just one part of the brain,' Kathuria said in a press statement. 'If you can understand what goes wrong early in development, we may be able to find new targets for drug screening.'
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Epoch Times
2 hours ago
- Epoch Times
Cowboys Owner Jerry Jones Announces He Is Cancer Free With New Treatment
Longtime Dallas Cowboys owner Jerry Jones, now cancer free, recently went public on his battle with Stage 4 melanoma via an interview with The Dallas Morning News and an upcoming Netflix series about the Cowboys that will air on Aug. 19. 'I was saved by a fabulous treatment and great doctors and a real miracle [drug] called PD-1 [therapy],' Jones told the paper. 'I went into trials for that PD-1, and it has been one of the great medicines. I now have no tumors.'


Business Wire
3 hours ago
- Business Wire
Lanier Law Firm Representing Health Choice Alliance in Litigation Alleging Eli Lilly Offered Kickbacks to Texas Health Care Providers
MARSHALL, Texas--(BUSINESS WIRE)--Texas Attorney General Ken Paxton has filed a lawsuit in state court against Eli Lilly and Co., accusing the pharmaceutical giant of bribing and inducing medical providers to prescribe its most profitable drugs. In return, physicians were offered unlawful payments and a range of free services in violation of state law. 'This scheme corrupted medical decision-making by giving doctors quid pro quo services obviously intended to influence prescribing,' says Mark Lanier of The Lanier Law Firm. Texas is intervening in the litigation as a plaintiff with the Health Choice Alliance, a research organization jointly represented by The Lanier Law Firm and McKool Smith PC. The lawsuit, filed in Harrison County, accuses Eli Lilly of offering the kickbacks to steer providers to write prescriptions for as many as 14 high-demand drugs such as the GLP-1 medications Mounjaro and Zepbound, resulting in millions of dollars in claims to the state's Medicaid program. Because those charges resulted from Eli Lilly's suspect marketing and service arrangements, the lawsuit claims the practice violated the Texas Health Care Program Fraud Prevention Act and Texas Anti-Kickback Statute. 'This scheme corrupted medical decision-making by giving doctors quid pro quo services obviously intended to influence prescribing,' says Mark Lanier of The Lanier Law Firm. 'As a result, Texas Medicaid became responsible for millions of dollars in improper payments. This case should serve as a warning to the other pharmaceutical giants that such unlawful activities will be investigated and prosecuted.' The lawsuit states that the company provided free nursing services to patients who were prescribed Eli Lilly drugs and offered a supposedly independent web-based service that was in fact managed by Eli Lilly to direct patients to the desired drugs. In addition, the kickbacks involved free services to physicians to obtain insurance authorizations and authorization from Texas Medicaid on behalf of patients, a time-consuming process with administrative costs that are not normally reimbursable to the provider. 'Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,' said Attorney General Paxton in announcing the lawsuit. 'Eli Lilly fraudulently sought to maximize profits at taxpayer expense and put corporate greed over people's health. I will not stand by while corporations unlawfully manipulate our healthcare system to line their own pockets.' The case is Texas vs. Eli Lilly & Co Inc., filed in the 71st District Court of Harrison County, Texas. About The Lanier Law Firm For more than 30 years, the men and women at The Lanier Law Firm have worked tirelessly, throughout the United States, to find unique and effective solutions for their clients. More than 50 skilled attorneys practice law in a broad array of areas, including business litigation, pharmaceutical litigation, asbestos exposure, oil and gas litigation, personal injury as well as defective and dangerous products, among others. Named an Elite Trial Law Firm by The National Law Journal, The Lanier Law Firm has offices in Houston, New York, and Los Angeles.
Yahoo
6 hours ago
- Yahoo
Popular weight-loss drugs linked to sudden vision loss, research suggests
New research has discovered certain weight-loss medications could be associated with an increased risk of serious eye conditions, and even vision loss. Two studies, published in JAMA, analyzed how semaglutide and tirzepatide — which include popular drugs like Ozempic, Wegovy, Mounjaro and Zepbound — impacted eye health in Americans with type 2 diabetes over a two-year period. One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN) – a rare eye condition that can lead to sudden vision loss due to lack of blood flow – in association with semaglutide and tirzepatide. Popular Weight-loss Medication Could Relieve Painful Arthritis Symptoms, Doctors Report Out of more than 159,000 study participants with type 2 diabetes, 35 developed NAION, compared to 19 people in the comparison group. The Ohio-based researchers also noted an increased risk of developing "other optic nerve disorders," identified in 93 patients. Read On The Fox News App Although the second study did not observe a "statistically significant difference" in NAION in GLP-1 drug users, there was a small increase in diabetic retinopathy, an eye disease that can damage the retina. Diabetic Patients Taking Glp-1s May Face Increased Risk Of Eye Disease, Study Suggests While individuals with type 2 diabetes on GLP-1s showed a modestly increased risk of diabetic retinopathy, the researchers concluded that fewer patients experienced sight-threatening complications from the disease. "These findings suggest that all patients with type 2 diabetes treated with GLP-1 RAs, regardless of preexisting diabetic retinopathy, should be regularly screened and monitored for potential complications," the study authors concluded. Sue Decotiis, M.D., a medical weight loss doctor in New York City, said she believes more studies are required to confirm the association between these drugs and vision loss, as these studies report some conflicting results. "NAION is a rare condition of the optic nerve that, although serious, has not really been shown to be increased by these studies," Decotiis, who was not involved in the research, told Fox News Digital. "We need more studies for certain." Diabetic patients already face a high incidence of eye disease related to blood flow and nerve damage, the expert noted. "Eye complications are often directly related to the degree or lack thereof of diabetes control." Click Here To Sign Up For Our Health Newsletter In most cases, GLP-1 drugs reduce the severity of type 2 diabetes, therefore reducing the incidence of eye diseases, Decotiis noted. These drugs have also been shown to reduce the risk of cardiovascular disease, like hypertension, and to improve circulation, which can improve eye health. For diabetics who are starting a GLP-1, Decotiis recommends having an exam done by an ophthalmologist and scheduling follow-up exams throughout treatment. "We should take precaution with methodical ophthalmic care for diabetics on these drugs," Decotiis said. "However, let's not throw the baby out with the bath water." For more Health articles, visit Novo Nordisk, maker of Ozempic and Wegovy, provided the following statement when contacted by Fox News Digital. "Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from the use of our medicines very seriously. NAION is a very rare eye disease, and it is not an adverse drug reaction for the marketed formulations of semaglutide (Ozempic, Rybelsus and Wegovy) as per the approved labels in the U.S." "Novo Nordisk, on its part, has conducted an analysis across randomized controlled clinical trials with GLP-1 receptor agonists, including a blinded ophthalmologist evaluation to confirm NAION diagnoses. Our current assessment is that these data do not suggest a causal relationship between GLP-1 RA use and NAION events."Original article source: Popular weight-loss drugs linked to sudden vision loss, research suggests Solve the daily Crossword